Skip to main content
. Author manuscript; available in PMC: 2025 Jan 1.
Published in final edited form as: Menopause. 2023 Nov 13;31(1):3–9. doi: 10.1097/GME.0000000000002280

Table 3.

Post-Treatment Minus Baseline Change in VMS and Sleep Outcomes by Satisfaction with VMS Control/Relief and Desired Continuation

Outcome Change Satisfied with VMS control/relief Desire to continue study medication/pills
Yes (n=426) No (n=426) Yes (n=385) No (n=457)
Mean SD Mean SD p-value Mean SD Mean SD p-value
VMS frequency per day −4.9 3.8 −1.5 3.3 <0.001 −4.7 4.2 −1.9 3.2 <0.001
VMS severity (1–3) −0.6 0.6 −0.2 0.5 <0.001 −0.6 0.5 −0.2 0.5 <0.001
VMS bother (1–4) −0.8 0.7 −0.2 0.5 <0.001 −0.8 0.7 −0.3 0.6 <0.001
VMS interference (HFRDIS) −2.3 2.3 −0.7 1.9 <0.001 −2.3 2.4 −0.9 1.8 <0.001
VMS interference (HFI) −3.0 2.6 −1.1 2.2 <0.001 −3.0 2.7 −1.2 2.2 <0.001
Insomnia severity (ISI) −5.1 5.0 −2.5 4.3 <0.001 −5.1 5.2 −2.7 4.3 <0.001
Sleep quality/disturbance (PSQI) −2.5 3.0 −1.3 2.7 <0.001 −2.7 3.0 −1.3 2.7 <0.001

HFI = Hot Flash Interference Scale 3 items, HFRDIS= Hot Flash Related Daily Interference Scale 10 items; ISI=Insomnia Severity Index; PSQI = Pittsburgh Sleep Quality Index; SD=standard deviation; VMS=vasomotor symptoms.